<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cytoa24341" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cytometry A</journal-id><journal-id journal-id-type="iso-abbrev">Cytometry A</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CYTO</journal-id><journal-title-group><journal-title>Cytometry</journal-title></journal-title-group><issn pub-type="ppub">1552-4922</issn><issn pub-type="epub">1552-4930</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8453800</article-id><article-id pub-id-type="pmcid-ver">PMC8453800.1</article-id><article-id pub-id-type="pmcaid">8453800</article-id><article-id pub-id-type="pmcaiid">8453800</article-id><article-id pub-id-type="pmid">33939254</article-id><article-id pub-id-type="doi">10.1002/cyto.a.24341</article-id><article-id pub-id-type="publisher-id">CYTOA24341</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Omip</subject></subj-group><subj-group subj-group-type="heading"><subject>Omip</subject></subj-group></article-categories><title-group><article-title>OMIP 074: Phenotypic analysis of <styled-content style="fixed-case" toggle="no">IgG</styled-content> and <styled-content style="fixed-case" toggle="no">IgA</styled-content> subclasses on human B cells</article-title><alt-title alt-title-type="left-running-head">Nettey et al.</alt-title></title-group><contrib-group><contrib id="cytoa24341-cr-0001" contrib-type="author"><name name-style="western"><surname>Nettey</surname><given-names initials="L">Leonard</given-names></name><xref rid="cytoa24341-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cytoa24341-cr-0002" contrib-type="author"><name name-style="western"><surname>Ballard</surname><given-names initials="R">Reid</given-names></name><xref rid="cytoa24341-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cytoa24341-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Liechti</surname><given-names initials="T">Thomas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8738-6679</contrib-id><xref rid="cytoa24341-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>thomas.liechti@nih.gov</email></address></contrib><contrib id="cytoa24341-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Mason</surname><given-names initials="RD">Rosemarie D.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7123-4902</contrib-id><xref rid="cytoa24341-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>rosemarie.mason@nih.gov</email></address></contrib></contrib-group><aff id="cytoa24341-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">ImmunoTechnology Section</named-content>
<institution>Vaccine Research Center, NIAID, NIH</institution>
<city>Bethesda</city>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Rosemarie D. Mason and Thomas Liechti, ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH, 40 Convent Dr., Room 5606B, Bethesda, MD 20892&#8208;3015, USA.<break/>
Email: <email>rosemarie.mason@nih.gov</email> (R. D. M.) and <email>thomas.liechti@nih.gov</email> (T. L.)<break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>5</month><year>2021</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2021</year></pub-date><volume>99</volume><issue seq="100">9</issue><issue-id pub-id-type="pmc-issue-id">390399</issue-id><issue-id pub-id-type="doi">10.1002/cyto.a.v99.9</issue-id><fpage>880</fpage><lpage>883</lpage><history><date date-type="rev-recd"><day>26</day><month>2</month><year>2021</year></date><date date-type="received"><day>16</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>09</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>27</day><month>09</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-07 02:25:20.220"><day>07</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">Published 2021. This article is a U.S. Government work and is in the public domain in the USA. <italic toggle="yes">Cytometry Part A</italic> published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CYTO-99-880.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CYTO-99-880.pdf"/><funding-group><award-group id="funding-0001"><funding-source>Intramural Research Program, Vaccine Research Center, NIAID</funding-source></award-group><award-group id="funding-0002"><funding-source>We thank Robert S. Balderas, Alan M. Stall, Brent Gaylord, Jacob L. Rabenstein, and Aaron J. Tyznik, of BD Biosciences, for providing conjugated test antibodies and advice on high parameter fluorescence flow cytometry through a Cooperative Research And Development Agreement with the Vaccine Research Center, NIAID, NIH</funding-source><award-id>CRADA # 2012&#8208;2467</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Institutes of Health
</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Research and Development
</institution><institution-id institution-id-type="doi">10.13039/100006190</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>BD Biosciences
</institution><institution-id institution-id-type="doi">10.13039/100011095</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="4"/><word-count count="3354"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2021</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.7 mode:remove_FC converted:21.09.2021</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cytoa24341-cit-9001"><string-name name-style="western"><surname>Nettey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ballard</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liechti</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mason</surname><given-names>RD</given-names></string-name>. <article-title>OMIP 074: Phenotypic analysis of <styled-content style="fixed-case" toggle="no">IgG</styled-content> and <styled-content style="fixed-case" toggle="no">IgA</styled-content> subclasses on human B cells</article-title>. <source>Cytometry</source>. <year>2021</year>;<volume>99</volume>:<fpage>880</fpage>&#8211;<lpage>883</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.a.24341</pub-id><pub-id pub-id-type="pmid">33939254</pub-id><pub-id pub-id-type="pmcid">PMC8453800</pub-id></mixed-citation>
</p><fn-group><fn id="cytoa24341-note-1002"><p><bold>Funding information</bold> Intramural Research Program, Vaccine Research Center, NIAID; We thank Robert S. Balderas, Alan M. Stall, Brent Gaylord, Jacob L. Rabenstein, and Aaron J. Tyznik, of BD Biosciences, for providing conjugated test antibodies and advice on high parameter fluorescence flow cytometry through a Cooperative Research And Development Agreement with the Vaccine Research Center, NIAID, NIH, Grant/Award Number: CRADA # 2012&#8208;2467; National Institutes of Health; Research and Development; BD Biosciences</p></fn></fn-group></notes></front><body id="cytoa24341-body-0001"><sec id="cytoa24341-sec-0001"><label>1</label><title>PURPOSE AND APPROPRIATE SAMPLE TYPES</title><p>This panel was designed and optimized to characterize the phenotypic diversity of circulating human memory B cells with an emphasis on discriminating IgA and IgG subclasses. Markers to detect all human immunoglobulin isotypes (IgA, IgD, IgE, IgG, and IgM), subclasses (IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4), and light chains (IgKappa and IgLambda) were used in combination with markers to more precisely delineate memory B cell populations based on CD21 and CD27. This panel has been tested on fresh and cryopreserved peripheral blood mononuclear cells (PBMC) from multiple healthy subjects (Table&#160;<xref rid="cytoa24341-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="cytoa24341-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Summary table for application of OMIP</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Purpose</th><th align="left" valign="bottom" rowspan="1" colspan="1">Phenotyping IgA and IgG subclasses on B cells</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Species</td><td align="left" valign="top" rowspan="1" colspan="1">Human</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cell types</td><td align="left" valign="top" rowspan="1" colspan="1">Fresh or cryopreserved PBMC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cross&#8208;references</td><td align="left" valign="top" rowspan="1" colspan="1">OMIP&#8208;003, OMIP&#8208;033, OMIP&#8208;043, OMIP&#8208;047, OMIP&#8208;051</td></tr></tbody></table></table-wrap></sec><sec id="cytoa24341-sec-0002"><label>2</label><title>BACKGROUND</title><p>Antibody discovery research has been instrumental in facilitating the isolation and characterization of therapeutic monoclonal antibodies (mAbs) for cancer [<xref rid="cytoa24341-bib-0001" ref-type="bibr">1</xref>], autoimmune diseases [<xref rid="cytoa24341-bib-0002" ref-type="bibr">2</xref>], and infectious diseases, such as influenza and human immunodeficiency virus&#8208;1 (HIV&#8208;1) [<xref rid="cytoa24341-bib-0003" ref-type="bibr">3</xref>, <xref rid="cytoa24341-bib-0004" ref-type="bibr">4</xref>]. The approaches to human antibody isolation include B cell immortalization, yeast or phage display, single B cell culture, and antigen&#8208;specific single B cell sorting [<xref rid="cytoa24341-bib-0005" ref-type="bibr">5</xref>]. The latter two methods rely on single&#8208;cell sorting of memory B cells and typically employ a dump/exclusion gate to remove contaminating T cells (CD3<sup>&#8722;</sup>CD4<sup>&#8722;</sup>CD8<sup>&#8722;</sup>), monocytes/macrophages (CD14<sup>&#8722;</sup>) and dead cells (viability dye), and a staining panel to include B cell markers (CD19<sup>+</sup>CD20<sup>+</sup>) and class&#8208;switched memory B cell markers (IgD<sup>&#8722;</sup>IgM<sup>&#8722;</sup>IgG<sup>+</sup>CD27<sup>+</sup>). Unfortunately, none of these antibody isolation methods are designed to capture B cell immunoglobulin subclass information which is typically assessed by separate analysis of serum or plasma samples by enzyme&#8208;linked immunosorbent assay (ELISA). Likewise, flow&#8208;based methods to provide a simultaneous readout of both antibody specificity and subclass rely on assaying soluble antibodies present in serum or plasma samples rather than phenotyping B cells directly [<xref rid="cytoa24341-bib-0006" ref-type="bibr">6</xref>]. Despite relatively minor differences in amino acid sequence, each immunoglobulin subclass has important functional differences with respect to antigen binding and stimulation of Fc receptor&#8208;mediated phagocytosis, antibody&#8208;dependent cell&#8208;mediated cytotoxicity (ADCC), and complement activation [<xref rid="cytoa24341-bib-0007" ref-type="bibr">7</xref>]. Thus, with growing interest in mining the antibody repertoire to identify functional antigen&#8208;specific mAbs from individual B cells, we designed and optimized a panel to capture antibody subclass information at the single&#8208;cell level (Figure&#160;<xref rid="cytoa24341-fig-0001" ref-type="fig">1</xref>, Table&#160;<xref rid="cytoa24341-tbl-0002" ref-type="table">2</xref>, Figures&#160;<xref rid="cytoa24341-supitem-0003" ref-type="supplementary-material">S1</xref> and <xref rid="cytoa24341-supitem-0004" ref-type="supplementary-material">S2</xref>).</p><fig position="float" fig-type="FIGURE" id="cytoa24341-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Gating strategy for phenotyping IgG and IgA subclasses on human B cells. (A) Example staining and gating of viable lymphocytes from human PBMC identified through sequential gating of time, single events, lymphocytes by light scatter and viable cells based on lack of signal with viability dye. (B) B cells can be identified by CD19<sup>+</sup> and/or CD20<sup>+</sup> expression. (C) The B cell population can be used to analyze B cell subsets based on CD21 and CD27 which enables the assessment of memory B cell maturation states (AM, activated memory; RM, resting memory; TLM, tissue&#8208;like memory) and BCR light chain usage. (D) Class&#8208;switched B cells can be defined based on the lack of IgD and IgM. A less strict gate was used as some markers such as IgG PE&#8208;Cy5 show low levels of SSE into channels V570 and G710. This potentially causes contamination with na&#239;ve B cells expressing low levels of IgM and IgD which will be excluded in the subsequent gating of IgG or IgA expressing B cells as shown in (F). (E) Mutual exclusive expression of IgG and IgE helps identify IgE<sup>+</sup> class&#8208;switched B cells. (F) Identification and enumeration of IgA<sup>+</sup> and IgG<sup>+</sup> subclass B cells is performed following a pre&#8208;gate on IgD<sup>&#8722;</sup>IgM<sup>&#8722;</sup> class&#8208;switched B cells to increase resolution of potentially dim markers. All anti&#8208;subclass antibodies co&#8208;stain with the appropriate anti&#8208;isotype antibody. Shown is data from one healthy individual [Color figure can be viewed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://wileyonlinelibrary.com" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CYTO-99-880-g001.jpg"/></fig><table-wrap position="float" id="cytoa24341-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Reagents used for OMIP</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Specificity</th><th align="left" valign="bottom" rowspan="1" colspan="1">Fluorochrome</th><th align="left" valign="bottom" rowspan="1" colspan="1">Clone</th><th align="left" valign="bottom" rowspan="1" colspan="1">Purpose</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">CD19</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Dazzle 594</td><td align="left" valign="top" rowspan="1" colspan="1">HIB19</td><td align="left" valign="top" rowspan="1" colspan="1">Lineage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD20</td><td align="left" valign="top" rowspan="1" colspan="1">Alexa Fluor 700</td><td align="left" valign="top" rowspan="1" colspan="1">2H7</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;Cell Subset</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD27</td><td align="left" valign="top" rowspan="1" colspan="1">BV650</td><td align="left" valign="top" rowspan="1" colspan="1">O323</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD21</td><td align="left" valign="top" rowspan="1" colspan="1">BV605</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;ly4</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgA</td><td align="left" valign="top" rowspan="1" colspan="1">DyLight 405</td><td align="left" valign="top" rowspan="1" colspan="1">Polyclonal (Goat)</td><td align="left" valign="top" rowspan="1" colspan="1">Immunoglobulin Isotype</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgD</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy5.5</td><td align="left" valign="top" rowspan="1" colspan="1">IADB6 (IA6&#8208;2)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgE</td><td align="left" valign="top" rowspan="1" colspan="1">APC&#8208;Fire 750</td><td align="left" valign="top" rowspan="1" colspan="1">MHE&#8208;18</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgG</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy5</td><td align="left" valign="top" rowspan="1" colspan="1">G18&#8208;145</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgM</td><td align="left" valign="top" rowspan="1" colspan="1">BV570</td><td align="left" valign="top" rowspan="1" colspan="1">MHM&#8208;88</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgA1</td><td align="left" valign="top" rowspan="1" colspan="1">PerCP&#8208;Cy5.5</td><td align="left" valign="top" rowspan="1" colspan="1">B3506B4</td><td align="left" valign="top" rowspan="1" colspan="1">Immunoglobulin subclass</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgA2</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Vio770</td><td align="left" valign="top" rowspan="1" colspan="1">IS11&#8208;21E11</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgG1</td><td align="left" valign="top" rowspan="1" colspan="1">PE</td><td align="left" valign="top" rowspan="1" colspan="1">HP6001</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgG2</td><td align="left" valign="top" rowspan="1" colspan="1">Biotin</td><td align="left" valign="top" rowspan="1" colspan="1">HP6002</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Biotin</td><td align="left" valign="top" rowspan="1" colspan="1">Streptavidin&#8208;BV750</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgG3</td><td align="left" valign="top" rowspan="1" colspan="1">Alexa Fluor 488</td><td align="left" valign="top" rowspan="1" colspan="1">HP6050</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgG4</td><td align="left" valign="top" rowspan="1" colspan="1">APC</td><td align="left" valign="top" rowspan="1" colspan="1">SAG4</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgKappa</td><td align="left" valign="top" rowspan="1" colspan="1">BV711</td><td align="left" valign="top" rowspan="1" colspan="1">G20&#8208;193</td><td align="left" valign="top" rowspan="1" colspan="1">Immunoglobulin light chain</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgLambda</td><td align="left" valign="top" rowspan="1" colspan="1">BV786</td><td align="left" valign="top" rowspan="1" colspan="1">JDC&#8208;12</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dead Cells</td><td align="left" valign="top" rowspan="1" colspan="1">Aqua Blue</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Viability</td></tr></tbody></table></table-wrap><p>This panel was developed as part of an antibody isolation pipeline and is primarily used for index sorting of single class&#8208;switched or antigen&#8208;specific B cells enabling deeper phenotyping of B cells identified to express antigen&#8208;specific BCR. We verified the performance of the panel on a sorter (FACSAria III, configuration in Table&#160;<xref rid="cytoa24341-supitem-0015" ref-type="supplementary-material">S1</xref>) and an analyzer (FACSymphony, configuration in Table&#160;<xref rid="cytoa24341-supitem-0016" ref-type="supplementary-material">S2</xref>) as shown in Figure&#160;<xref rid="cytoa24341-supitem-0005" ref-type="supplementary-material">S3</xref>.</p><p>Therefore, the panel can be used on different platforms equipped with distinct hardware. To maintain compatibility with the analyzer and cell sorter laser and filter configurations, three blue laser detectors, and all ultraviolet laser detectors were excluded from consideration in panel development (Tables&#160;<xref rid="cytoa24341-supitem-0015" ref-type="supplementary-material">S1</xref> and <xref rid="cytoa24341-supitem-0016" ref-type="supplementary-material">S2</xref>).</p><p>B cells can be defined by expression of the pan B cell markers CD19 and CD20 with the combination facilitating discrimination of plasmablasts (which downregulate CD20 but retain CD19 expression) from all other B cell subsets in the periphery (Figure&#160;<xref rid="cytoa24341-fig-0001" ref-type="fig">1B</xref>). While pre&#8208;gating of class&#8208;switched IgD&#8208;IgM&#8208; cells is sufficient for further analysis of IgA and IgG subclasses, we also included CD21 and CD27 to delineate additional memory B cell populations, including activated memory (CD21<sup>low</sup>CD27<sup>+</sup>), resting memory (CD21<sup>high</sup>CD27<sup>+</sup>), and exhausted memory (CD21<sup>low</sup>CD27<sup>&#8722;</sup>) B cells [<xref rid="cytoa24341-bib-0008" ref-type="bibr">8</xref>] (Figure&#160;<xref rid="cytoa24341-fig-0001" ref-type="fig">1C</xref>).</p><p>We briefly considered the inclusion of markers against T cells, natural killer (NK) cells, and monocytes to increase the purity of cells analyzed and sorted. However, in order to include antibodies against all immunoglobulin isotypes as well as IgA and IgG subclasses, we removed antibodies typically used for a dump channel as the total number of non&#8208;B cell markers expressed in the CD19<sup>+</sup> population was minimal for all donors tested (Figure&#160;<xref rid="cytoa24341-supitem-0006" ref-type="supplementary-material">S4</xref>).</p><p>Additionally, positive gating on immunoglobulin isotypes further minimizes the likelihood of including cells that express non&#8208;B cell surface proteins in analysis or sorting.</p><p>Pan&#8208;IgA, pan&#8208;IgG, IgD, IgM, and IgE were included to define immunoglobulin isotypes of individual B cells while IgA and IgG subclasses were delineated using IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4 (Figures&#160;<xref rid="cytoa24341-fig-0001" ref-type="fig">1E</xref> and <xref rid="cytoa24341-supitem-0005" ref-type="supplementary-material">S5</xref>A&#8211;C).</p><p>We verified that immunoglobulin isotypes are exclusively expressed, each subclass within the IgA and IgG isotypes is exclusively expressed, and all isotype cells are accounted for by the sum of the subclasses (e.g., IgA1&#8201;+&#8201;IgA2&#160;=&#160;pan IgA; IgG1&#8201;+&#8201;IgG2&#8201;+&#8201;IgG3&#8201;+&#8201;IgG4&#160;=&#160;pan IgG) (Figure&#160;<xref rid="cytoa24341-supitem-0004" ref-type="supplementary-material">[Link]</xref>, <xref rid="cytoa24341-supitem-0007" ref-type="supplementary-material">[Link]</xref>B&#8211;D). We also employed stepwise, sequential staining to prevent competition between immunoglobulin isotype&#8208; and subclass&#8208;specific antibodies (Figure&#160;<xref rid="cytoa24341-supitem-0008" ref-type="supplementary-material">S6</xref>) and included anti&#8208;kappa and anti&#8208;lambda chain antibodies in the panel to confirm functional B cell receptor expression (Figures&#160;<xref rid="cytoa24341-fig-0001" ref-type="fig">1C</xref> and <xref rid="cytoa24341-supitem-0009" ref-type="supplementary-material">S7</xref>).</p><p>In summary, this panel allows for thorough analysis and targeted isolation of single B cells based on immunoglobulin isotype and subclass expression. This is especially relevant as each IgG subclass has been shown to have a unique profile that reflects its distinct structure, FcR binding and signaling capacity, immune complex formation, complement activation, and resulting downstream effector functions [<xref rid="cytoa24341-bib-0007" ref-type="bibr">7</xref>, <xref rid="cytoa24341-bib-0009" ref-type="bibr">9</xref>]. Thus, the ability to characterize B cell IgA/IgG subclass profile at the single B cell level will facilitate a better understanding of the link between antibody specificity, effector function, and protective efficacy in various human diseases [<xref rid="cytoa24341-bib-0010" ref-type="bibr">10</xref>].</p></sec><sec id="cytoa24341-sec-0003"><label>3</label><title>SIMILARITIES TO OTHER <styled-content style="fixed-case" toggle="no">OMIPS</styled-content>
</title><p>Previous OMIPs focused on human peripheral B cells [<xref rid="cytoa24341-bib-0011" ref-type="bibr">11</xref>, <xref rid="cytoa24341-bib-0012" ref-type="bibr">12</xref>, <xref rid="cytoa24341-bib-0013" ref-type="bibr">13</xref>, <xref rid="cytoa24341-bib-0014" ref-type="bibr">14</xref>] or contain markers to define major B cell subsets [<xref rid="cytoa24341-bib-0015" ref-type="bibr">15</xref>]. In addition, similar to this panel, OMIP&#8208;043 and &#8208;051 included pan&#8208;IgA and &#8208;IgG specific reagents and OMIP&#8208;047 enables the analysis of IgG1, IgG3, and IgA on B cells. Noteworthy, OMIP&#8208;043 focuses on plasmablasts and incorporates intracellular staining of IgG and IgA to accommodate for the switch from surface B cell receptors to secreted immunoglobulins in plasmablasts. However, this panel is unique as none of the existing OMIPs enables the precise delineation of all known immunoglobulin subclasses and their phenotypic characteristics. Therefore, our panel is a useful addition to the OMIP series.</p></sec><sec id="cytoa24341-sec-0005"><title>AUTHOR CONTRIBUTIONS</title><p><bold>Leonard Nettey:</bold> Conceptualization; data curation; formal analysis; methodology; validation; visualization; writing&#8208;original draft; writing&#8208;review &amp; editing. <bold>Reid Ballard:</bold> Data curation; formal analysis; methodology; validation; visualization. <bold>Thomas Liechti:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; supervision; validation; visualization; writing&#8208;review &amp; editing. <bold>Rosemarie Mason:</bold> Conceptualization; data curation; formal analysis; investigation; project administration; resources; supervision; visualization; writing&#8208;original draft; writing&#8208;review &amp; editing.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cytoa24341-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Appendix</bold> S1. Supporting Information</p><p><bold>MIFlowCyt</bold>&#8208;Compliant Items</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s015.doc" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Appendix</bold> S2. Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s005.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S1 Concatenate display of titrations for all reagents used in the final panel.</bold> Reagents were titrated using unstained lymphocytes or B cells pre&#8208;stained with anti&#8208;CD19, anti&#8208;CD20, anti&#8208;IgD and anti&#8208;IgM as indicated. Biotin&#8208;labeled anti&#8208;IgG2 was detected using streptavidin PE&#8208;CF594 and streptavidin&#8208;BV750 was titrated using cells pre&#8208;stained with biotin&#8208;labeled anti&#8208;IgG1. Optimal titers, selected based on visual inspection, are highlighted in red.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s006.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S2 NxN plots of all anti&#8208;immunoglobulin reagents.</bold> Where possible, combinations predicted to cause high spillover spread error (e.g. PerCP&#8208;Cy5.5 and PE&#8208;Cy5.5) are used to detect orthogonal antigens (e.g. IgA1 and IgD, respectively).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s009.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S3 Validation of anti&#8208;subclass antibodies. A)</bold> A pre&#8208;gate on IgD&#8208;IgM&#8208; B cells is used to assist in the identification of IgA+ and IgG+ B cells. <bold>B)</bold> Antibodies against IgA1 and IgA2 account for all IgA+ B cells. <bold>C)</bold> Antibodies against IgG1, IgG2, IgG3, and IgG4 account for all IgG+ B cells. <bold>D)</bold> Expression of individual IgG subclasses is mutually exclusive.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s011.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0006" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S4 Comparison of panel acquired on Aria III and FACSymphony.</bold> Cryopreserved PBMC from 2 separate donors stained with the final panel were analyzed with a FACSymphony (configuration in Online Table&#160;<xref rid="cytoa24341-tbl-0001" ref-type="table">1</xref>) and FACSAria III (configuration in Online Table&#160;<xref rid="cytoa24341-tbl-0002" ref-type="table">2</xref>) shown in the first and second row from each donor, respectively. IgE staining is not shown due to the lack of IgE<sup>+</sup> B cells in these samples.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s012.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0007" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S5 Expression of kappa and lambda light chains on human B cell subsets.</bold> Expression of light chains is lower in IgA+ than IgG+ B cells and this is consistent across multiple healthy donor PBMC. B cells that are IgD&#8208;IgM&#8208;IgA&#8208;IgG&#8208; are low or negative in overall immunoglobulin expression (determined by expression of immunoglobulin kappa or lambda light chains) and may not be detected by the antibodies used in this OMIP.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s008.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0008" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S6 Sequential staining to eliminate competition between pan&#8208;IgA and IgA subclass&#8208;specific antibodies.</bold> Healthy donor PBMC were stained with anti&#8208;pan&#8208;IgA either concurrently (left panels) with antibodies against immunoglobulin subclasses (including IgA1, IgA2 and IgG4) or in a subsequent step following two washes (middle panels). Overlay plots of co&#8208;stained (red) and 2&#8208;step stained (blue) PBMC are shown in right panels. <bold>A)</bold> An IgA&#8201;+&#8201;IgG4+ population appears in the concurrently stained sample but is significantly reduced in the sequentially stained sample, implying that the anti&#8208;IgG4 reagent may bind to some clones of the polyclonal goat IgGs within the anti&#8208;pan&#8208;IgA reagent. <bold>B)</bold> The IgA1 signal is decreased to the point of incomplete separation between positive and negative cells when anti&#8208;pan&#8208;IgA is stained concurrently with anti&#8208;IgA subclass antibodies (top panels).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s018.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0009" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S7 Non&#8208;B cell marker expression on live&#8201;+&#8201;CD19+ cells. A)</bold> FACS plots for Donor 1 displaying expression of non&#8208;B cell markers CD3 (clone SK7, ThermoFisher), CD14 (clone M5E2, BD Biosciences), CD16 (clone 3G8, BD Biosciences) and CD56 (clone NCAM16.2, BD Biosciences) in a Live+CD19+ population compared with total lymphocytes. <bold>B)</bold> Very few non&#8208;B cells are captured in the Live+CD19+ gate relative to the total number of Live+CD19+ B cells (45,573). Among 3 donors tested, less than 4% of Live+CD19+ cells would be expected to express one or more non&#8208; B cell markers.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s014.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0010" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S8 Distribution of IgA and IgG subclasses in peripheral blood.</bold> Cryopreserved PBMC from 3 donors stained with the full panel showing relative frequency of IgA and IgG isotype and subclass cells.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s013.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0011" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S9 Validation of anti&#8208;IgE antibody clones. A)</bold> Multiple anti&#8208;IgE antibody clones were validated using a panel that included basophil&#8208;identifying reagents CD123 (fluorochrome BB660, clone 7G3, BD Biosciences) and HLA&#8208;DR (fluorochrome BUV661, clone G46&#8208;6). Expression of IgE receptor FceRIa (clone AER&#8208;37/CRA&#8208;1, BioLegend) on basophils is correlated with anti&#8208;IgE binding. <bold>B)</bold> IgE binding is also correlated between anti&#8208;IgE clones REA1049, MHE&#8208;18, and MB10&#8208;5C4. IgE&#8208;expressing B cells are expected to be rare or absent in typical healthy donor PBMC. Anti&#8208;IgE reagents occasionally bind to B cells non&#8208;specifically, but none of the clones tested on this donor display binding to IgA<sup>&#8722;</sup>IgD<sup>&#8722;</sup>IgG<sup>&#8722;</sup>IgM<sup>&#8722;</sup> B cells. Upper and lower triangle shows IgE staining on CD123<sup>+</sup>HLA&#8208;DR<sup>&#8722;</sup> basophils and IgA<sup>&#8722;</sup>IgD<sup>&#8722;</sup>IgM<sup>&#8722;</sup>IgG<sup>&#8722;</sup> B cells, respectively.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s021.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0012" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S10 Panel iteration #6.</bold> Example staining and gating of human PBMC using reagents from panel iteration #6 as listed in Online Table 5.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s019.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0013" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S11 Panel iteration #7.</bold> Example staining and gating of human PBMC using reagents from panel iteration #7 as listed in Online Table 5.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s016.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0014" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Figure S12 Influence of fixation with 0.5% PFA on panel performance.</bold> Cryopreserved PBMC from 3 donors stained with the final panel were analyzed with a FACSAria III (configuration in Online Table&#160;<xref rid="cytoa24341-tbl-0001" ref-type="table">1</xref>) prior to fixation and 30&#8201;minutes and 24&#8201;hours after fixation. Example data from one donor is shown. First row shows staining prior to fixation and middle and last rows depict staining after 30&#8201;minutes and 24&#8201;hours of fixation, respectively.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s017.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0015" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Table S1 Optical configuration of BD FACSymphony A5 cytometer.</bold> The panel was validated using a BD FACSymphony A5 cytometer with the listed optical elements. Long pass dichroic filters and Diode Pumped Solid State (DPSS) lasers were used throughout the instrument.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s007.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0016" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Table S2 Optical configuration of BD FACSAria III cell sorter.</bold> The panel was developed for use with the BD FACSAria III cell sorter with the listed optical elements. Long pass dichroic filters and Diode Pumped Solid State (DPSS) lasers were used throughout the instrument.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s020.tiff" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0017" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Table S3 Commercial reagents.</bold> Anti&#8208;IgA was reconstituted with 1&#160;mL dH<sub>2</sub>O per manufacturer recommendations. Aqua Blue viability dye was reconstituted with 50&#8201;&#956;L dimethyl sulfoxide (DMSO) and stored at &#8208;30C.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0018" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Table S4 Custom and in&#8208;house conjugated reagents.</bold> Anti&#8208;IgA1 and anti&#8208;IgD reagents were ordered unlabeled from Southern Biotech and labeled with PerCP&#8208;Cy5.5 and PE&#8208;Cy5.5, respectively, using Lightning&#8208;Link Antibody Labeling Kits from Novus Biologicals. BD, Becton Dickinson.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s004.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0019" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Table S5 Primary iterations of panel development.</bold> Primary iterations of panel development, including antibody specificity, fluorochrome, and clone, if applicable, as well as reagent changes for each panel (green). The viability marker (gray), was unchanged throughout all panels.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s002.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0020" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Table S6 Reagents tested but not used in this panel.</bold> All reagents tested were titrated on healthy donor PBMC and several were included in iterations during panel development.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24341-supitem-0021" position="float" content-type="local-data" orientation="portrait"><caption><p><bold>Table S7 Spillover Spread Matrix (SSM).</bold> The effect of a dye (row) on the resolution in a detector (column) is quantified in this matrix. Empirical observations have determined that combinations with SSM values greater than 4 (highlighted in red text) potentially display spillover spreading error in this panel. This matrix was generated in FlowJo version 9 using PBMC stained with panel reagents.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-99-880-s010.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cytoa24341-sec-0004"><title>ACKNOWLEDGMENTS</title><p>The authors thank Robert S. Balderas, Alan M. Stall, Brent Gaylord, Jacob L. Rabenstein, and Aaron J. Tyznik, of BD Biosciences, for providing conjugated test antibodies and advice on high parameter fluorescence flow cytometry through a Cooperative Research and Development Agreement with the Vaccine Research Center, NIAID, NIH (CRADA # 2012&#8208;2467). In addition, the authors would like to thank the VRC flow core facility for instrumentation characterization and maintenance, and Margaret Beddall for the maintenance of the reagent repository and in&#8208;house conjugations. This work was supported by the intramural research program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).</p></ack><ref-list id="cytoa24341-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="cytoa24341-bib-0001"><label>1</label><mixed-citation publication-type="book" id="cytoa24341-cit-0001"><string-name name-style="western"><surname>Marrocco</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Romaniello</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yarden</surname><given-names>Y</given-names></string-name>. <part-title>Cancer immunotherapy: the Dawn of antibody cocktails</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Steinitz</surname><given-names>M</given-names></string-name></person-group>, editor. <source>Human monoclonal antibodies. Methods in molecular biology</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Humana Press</publisher-name>; <year>2019</year>, <year>1904</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-8958-4_2</pub-id><pub-id pub-id-type="pmid">30539465</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0002"><string-name name-style="western"><surname>Yoo</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>SH</given-names></string-name>. <article-title>Targets of monoclonal antibodies for immunological diseases</article-title>. <source>Arch Pharm Res</source>. <year>2018</year>;<volume>42</volume>:<fpage>293</fpage>&#8211;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-018-1087-2</pub-id>.<pub-id pub-id-type="pmid">30426387</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0003"><string-name name-style="western"><surname>Corti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cameroni</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Guarino</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kallewaard</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></string-name>. <article-title>Tackling influenza with broadly neutralizing antibodies</article-title>. <source>Curr Opin Virol</source>. <year>2017</year>;<volume>24</volume>:<fpage>60</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28527859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2017.03.002</pub-id><pub-id pub-id-type="pmcid">PMC7102826</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0004"><string-name name-style="western"><surname>McCoy</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Burton</surname><given-names>DR</given-names></string-name>. <article-title>Identification and specificity of broadly neutralizing antibodies against HIV</article-title>. <source>Immunol Rev</source>. <year>2017</year>;<volume>275</volume>:<fpage>11</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">28133814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12484</pub-id><pub-id pub-id-type="pmcid">PMC5299474</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0005"><string-name name-style="western"><surname>Voigt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Semenova</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Etienne</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>CQ</given-names></string-name>. <article-title>Therapeutic antibody discovery in infectious diseases using single&#8208;cell analysis</article-title>. <source>Adv Exp Med Biol</source>. <year>2018</year>;<volume>1068</volume>:<fpage>89</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">29943298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-13-0502-3_8</pub-id><pub-id pub-id-type="pmcid">PMC9022094</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0006"><string-name name-style="western"><surname>Brown</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Licht</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Dugast</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bailey&#8208;Kellogg</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alter</surname><given-names>G</given-names></string-name>, et al. <article-title>High&#8208;throughput, multiplexed IgG subclassing of antigen&#8208;specific antibodies from clinical samples</article-title>. <source>J Immunol Methods</source>. <year>2018</year>;<volume>386</volume>:<fpage>117</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jim.2012.09.007</pub-id><pub-id pub-id-type="pmcid">PMC3475184</pub-id><pub-id pub-id-type="pmid">23023091</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0007"><string-name name-style="western"><surname>de Taeye</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Rispens</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Vidarsson</surname><given-names>G</given-names></string-name>. <article-title>The ligands for human IgG and their effector functions</article-title>. <source>Antibodies</source>. <year>2019</year>;<volume>8</volume>(<issue>2</issue>):<fpage>30</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antib8020030</pub-id><pub-id pub-id-type="pmcid">PMC6640714</pub-id><pub-id pub-id-type="pmid">31544836</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0008"><string-name name-style="western"><surname>Moir</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></string-name>. <article-title>B cells in HIV infection and disease</article-title>. <source>Nat Rev Immunol</source>. <year>2009</year>;<volume>9</volume>:<fpage>235</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">19319142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2524</pub-id><pub-id pub-id-type="pmcid">PMC2779527</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0009"><string-name name-style="western"><surname>Vidarsson</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dekkers</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rispens</surname><given-names>T</given-names></string-name>. <article-title>IgG subclass and allotypes: from structure to effector functions</article-title>. <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>:<fpage>520</fpage>.<pub-id pub-id-type="pmid">25368619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2014.00520</pub-id><pub-id pub-id-type="pmcid">PMC4202688</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0010"><string-name name-style="western"><surname>Irani</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Guy</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Andrew</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Beeson</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Ramsland</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Richards</surname><given-names>JS</given-names></string-name>. <article-title>Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases</article-title>. <source>Mol Immunol</source>. <year>2015</year>;<volume>67</volume>:<fpage>171</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">25900877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2015.03.255</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0011"><string-name name-style="western"><surname>Wei</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sanz</surname><given-names>I</given-names></string-name>. <article-title>OMIP&#8208;003: phenotypic analysis of human memory B cells</article-title>. <source>Cytometry A</source>. <year>2011</year>;<volume>79</volume>(<issue>11</issue>):<fpage>894</fpage>.<pub-id pub-id-type="pmid">21796774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.21112</pub-id><pub-id pub-id-type="pmcid">PMC3199331</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0012"><string-name name-style="western"><surname>Carrell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Groves</surname><given-names>CJ</given-names></string-name>. <article-title>OMIP&#8208;043: identification of human antibody secreting cell subsets</article-title>. <source>Cytometry A</source>. <year>2018</year>;<volume>93</volume>(<issue>2</issue>):<fpage>190</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">29286577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.23305</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0013"><string-name name-style="western"><surname>Liechti</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gunthard</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Trkola</surname><given-names>A</given-names></string-name>. <article-title>OMIP&#8208;047: high&#8208;dimensional phenotypic characterization of B cells</article-title>. <source>Cytometry A</source>. <year>2018</year>;<volume>93</volume>(<issue>6</issue>):<fpage>592</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">29782066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.23488</pub-id><pub-id pub-id-type="pmcid">PMC6704361</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0014"><string-name name-style="western"><surname>Liechti</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Roederer</surname><given-names>M</given-names></string-name>. <article-title>OMIP&#8208;051: 28&#8208;color flow cytometry panel to characterize B cells and myeloid cells</article-title>. <source>Cytometry A</source>. <year>2019</year>;<volume>95</volume>(<issue>2</issue>):<fpage>150</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">30549419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.23689</pub-id><pub-id pub-id-type="pmcid">PMC6546165</pub-id></mixed-citation></ref><ref id="cytoa24341-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cytoa24341-cit-0015"><string-name name-style="western"><surname>Brodie</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rothaeusler</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sospedra</surname><given-names>M</given-names></string-name>. <article-title>OMIP&#8208;033: a comprehensive single step staining protocol for human T&#8208; and B&#8208;cell subsets</article-title>. <source>Cytometry A</source>. <year>2016</year>;<volume>89</volume>(<issue>7</issue>):<fpage>629</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27276654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22889</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>